Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(7 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(1 year, 1 month from now) | |
US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(6 years from now) | |
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(11 years from now) | |
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication (I) | Nov 5, 2023 |
M (M) | May 9, 2025 |
Pediatric Exclusivity (PED) | Nov 9, 2025 |
Market Authorisation Date: 20 July, 2011
Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Red...
Dosage: TABLET;ORAL